TCGA-77-A5G1-01A-11R-A27Q-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 75
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.420
- PROTEIN_SECRETION+0.410
- IL6_JAK_STAT3_SIGNALING+0.340
- APICAL_JUNCTION+0.330
- INFLAMMATORY_RESPONSE+0.330
- TNFA_SIGNALING_VIA_NFKB+0.330
- ANDROGEN_RESPONSE+0.290
- UV_RESPONSE_DN+0.290
- APICAL_SURFACE+0.280
Top 10 suppressed
- E2F_TARGETS-0.340
- INTERFERON_ALPHA_RESPONSE-0.250
- SPERMATOGENESIS-0.210
- FATTY_ACID_METABOLISM-0.180
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.180
- HEDGEHOG_SIGNALING-0.130
- DNA_REPAIR-0.120
- G2M_CHECKPOINT-0.120
- KRAS_SIGNALING_DN-0.090
- XENOBIOTIC_METABOLISM-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ULC1700T_S19 | — | cohortMD2 | 0.815 |
| 2 | C3L-01838 | — | cohortSQ1 | 0.803 |
| 3 | MDT-AP-3024 | Med | Medulloblastoma | 0.801 |
| 4 | TCGA-DQ-5624-01A-01R-1873-07 | — | — | 0.800 |
| 5 | TCGA-CV-7236-01A-11R-2016-07 | — | — | 0.799 |
| 6 | TCGA-EW-A1PG-01A-11R-A144-07 | — | A | 0.798 |
| 7 | TCGA-43-6647-01A-11R-1820-07 | — | cohortSQ1 | 0.798 |
| 8 | 299613f5-2f9a-4687-ab0c-323bf38f3699 | — | — | 0.791 |
| 9 | c2ccc6b3-34d8-47c5-9367-cc53aad1622e | — | — | 0.790 |
| 10 | TCGA-46-3767-01A-01R-0980-07 | — | cohortSQ1 | 0.786 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.460 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.420 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.410 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.340 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.330 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.330 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.330 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.290 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.290 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.280 | Temsirolimus | — uncovered |
| ANGIOGENESIS | 0.270 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.260 | Idelalisib | — uncovered |
| COAGULATION | 0.240 | Binimetinib | — uncovered |
| APOPTOSIS | 0.210 | Idelalisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.190 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.190 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.180 | Idelalisib | — uncovered |